Fulcrum therapeutics inc qtrly loss per share $0.81

Fulcrum therapeutics - expects existing cash will be sufficient to enable it to fund its operating expenses into q3 2021 .fulcrum therapeutics reports recent business highlights and first quarter 2020 financial results.fulcrum therapeutics - as of march 31, cash, cash equivalents, marketable securities were $81.2 million, as compared to $96.7 million as of dec 31, 2019.fulcrum therapeutics inc qtrly loss per share $0.81.
FULC Ratings Summary
FULC Quant Ranking